{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-21-000990","form_type":"8-K","ticker":"CRL","cik":"0001100682","company_name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","filed_at":"2021-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:04:17.151136+00:00","generated_at":"2026-06-29T22:20:32.817451+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Charles River Q2 revenue $914.6M (+34% YoY); raises 2021 guidance above prior estimates","bullets":["Revenue $914.6M, +34% YoY (organic +24.1%); GAAP EPS $1.72, non-GAAP EPS $2.61.","Non-GAAP EPS of $2.61 beat prior year $1.58; net income $88.4M GAAP, $133.8M non-GAAP.","All three segments drove organic growth: RMS +44.5%, DSA +18.1%, Manufacturing +26.6%.","2021 guidance raised: revenue growth 20.5-22.5% (was 19-21%), non-GAAP EPS $10.10-$10.35 (was $9.75-$10.00), FCF ~$500M.","CEO cites robust client demand and strengthened portfolio; company adding staff and capacity."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-21-000990","json":"https://secwatch.observer/filing/0001157523-21-000990.json","markdown":"https://secwatch.observer/filing/0001157523-21-000990.md","text":"https://secwatch.observer/filing/0001157523-21-000990.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1100682/000115752321000990/0001157523-21-000990-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1100682/000115752321000990/a52470970.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T22:20:32.817451+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}